China National Pharmaceutical Group

China National Pharmaceutical Group Corp. (CNPGC) known as Sinopharm is a Chinese state-owned enterprise. The corporation was the indirect major shareholder of publicly traded companies Sinopharm Group (SEHK: 1099, via a 51–49 joint venture, Sinopharm Industrial Investment, with Fosun Pharmaceutical), China Traditional Chinese Medicine (SEHK: 570, mostly via Sinopharm Group Hongkong Co., Ltd.).[4] Shanghai Shyndec Pharmaceutical (SSE: 600420, via a wholly owned research institute based in Shanghai) and Beijing Tiantan Biological Products (SSE: 600161, via China National Biotec Group).

"Sinopharm" redirects here. For other uses, see Sinopharm (disambiguation).
China National Pharmaceutical Group
Sinopharm
state-owned enterprise
Founded1998
Headquarters
Beijing
,
China
Area served
China, exported worldwide
Key people
Guo Jianxin (Chairman & Party Committee Secretary)[1][2]
Revenue CN¥247.110 billion (2014)
CN¥8.758 billion (2014)
CN¥2.705 billion (2014)
Total assets CN¥199.192 billion (2014)
Total equity CN¥31.944 billion (2014)
OwnerChinese central government (100%)
ParentSASAC of the State Council
Subsidiaries
  • Sinopharm Industrial Investment (51%)
  • → Sinopharm Group (56.79%)
  • Trad. Chinese Medicine (37.59%)
  • Shyndec Pharma. (41.62%)
  • China National Biotec Group (95%)
  • → Tiantan Biological (53.30%)
Chinese name
Simplified Chinese中国医药集团总公司
Traditional Chinese中國醫藥集團總公司
short Chinese name
Simplified Chinese国药集团
Traditional Chinese國藥集團
Websitewww.sinopharm.com 
Footnotes / references
in a consolidated basis; equity and profit excluded minority interests; in Chinese Accounting Standards[3]

China National Pharmaceutical Group was supervised by the State-owned Assets Supervision and Administration Commission of the State Council.[5]

Several Sinopharm's subsidiary, such as China Sinopharm International Corp. and China National Pharmaceutical Foreign Trade Corp. were remained unlisted, which was not injected to Sinopharm Group.

Sinopharm was ranked 205th in 2016 Fortune Global 500 list.[6]

History

China National Pharmaceutical Corporation (Chinese: 中国医药(集团)公司)

One of its subsidiaries is the Wuhan Institute of Biological Products Co Ltd. a biotechnology company based in Wuhan, specializing in vaccines. It was fined for selling 400,520 ineffective DPT vaccines in November 2017.[7]

China National Pharmaceutical Group Corporation

China National Pharmaceutical Group Corporation (Chinese: 中国医药集团总公司) was founded in 1998 as a holding company for China National Pharmaceutical Corporation, China National Pharmaceutical Industry Corporation (Chinese: 中国医药工业公司), China National Pharmaceutical Foreign Trade Corp. (Chinese: 中国医药对外贸易公司) and China National Medical Device (Chinese: 中国医疗器械工业公司). In 2009 it was merged with China National Biotec Group (Chinese: 中国生物技术集团公司).

COVID-19 Vaccine development

In April 2020, China approved a clinical trial for a candidate COVID-19 vaccine developed by Sinopharm's Wuhan Institute of Biological Products.[8] The vaccine is a chemically-inactivated whole virus vaccine for COVID-19. On August 13, Sinopharm published results of its Phase I and Phase II clinical studies in the Journal of the American Medical Association based on data from 320 healthy adults in its trials. The report noted the inactivated COVID-19 vaccine had a low rate of adverse reactions and demonstrated immunogenicity, but longer-term assessment of safety and efficacy would require phase III trials.[9]

In late July 2020, Sinopharm began conducting Phase III vaccine trials in the United Arab Emirates in collaboration with G42 Healthcare, an Abu Dhabi-based artificial intelligence and cloud computing company, on 15,000 volunteers, all health professionals. In early august, all 15,000 eligible volunteers had received their first of two doses and would be inoculated with the second within the next few weeks.[10] In early August 2020, Sinopharm began conducting additional Phase III vaccine trials in Brazil's Parana state with the Parana Technology Institute (Tecpar) saying they would soon finalize their proposal and submit it for approval with federal health regulator Anvisa. [11] On 10 August 2020, Sinopharm began Phase III clinical trials in Bahrain which will include around 6,000 citizens and resident volunteers over 12 months. [12] Sinopharm also began working with the University of Karachi on vaccine trials, which if successful Pakistan would receive enough doses early in distribution to vaccinate about one-fifth of its population. [13]

gollark: 4
gollark: We have dedicated channels in which you can advocate for things like Rust or advocacy. Also, constrained writing (e.g. write without "a").
gollark: Advocacy
gollark: 3
gollark: We have dedicated channels in which you can advocate for things like Rust or advocacy.

References
  1. "中国医药集团总公司郭建新职务变动情况" (in Chinese). SASAC of the State Council. 6 May 2014. Retrieved 22 November 2016.
  2. "管理团队" (in Chinese). Sinopharm. Retrieved 22 November 2016.
  3. "中国医药集团总公司2016年度第一期超短期融资券发行披露材料" [Pospectus of 2016 (batch 1) Ultra-short-term financing of Sinopharm]. Sinopharm (in Chinese). Shanghai Clearing House. 19 January 2016. Retrieved 22 November 2016.
  4. "2015 Annual Report" (PDF). China Traditional Chinese Medicine. Hong Kong Stock Exchange. 28 April 2016. Retrieved 22 November 2016.
  5. "央企名录 (List of Central SOEs)". Official website of SASAC (in Chinese). Retrieved 3 March 2016.
  6. http://beta.fortune.com/global500/sinopharm-205
  7. "Chinese President Xi Jinping orders crackdown over 'appalling' vaccine scandal". South China Morning Post. 23 July 2018. Retrieved 29 November 2018.
  8. Zhang Zhihao (15 April 2020). "Three COVID-19 vaccines approved for clinical trials". China Daily. Retrieved 23 April 2020.
  9. Xia, Shengli; Duan, Kai; Zhang, Yuntao; Zhao, Dongyang; Zhang, Huajun; Xie, Zhiqiang; Li, Xinguo; Peng, Cheng; Zhang, Yanbo; Zhang, Wei; Yang, Yunkai; Chen, Wei; Gao, Xiaoxiao; You, Wangyang; Wang, Xuewei; Wang, Zejun; Shi, Zhengli; Wang, Yanxia; Yang, Xuqin; Zhang, Lianghao; Huang, Lili; Wang, Qian; Lu, Jia; Yang, Yongli; Guo, Jing; Zhou, Wei; Wan, Xin; Wu, Cong; Wang, Wenhui; Huang, Shihe; Du, Jianhui; Meng, Ziyan; Pan, An; Yuan, Zhiming; Shen, Shuo; Guo, Wanshen; Yang, Xiaoming (13 August 2020). "Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials". JAMA. doi:10.1001/jama.2020.15543.
  10. "Coronavirus: 15,000 register as volunteers for Covid-19 vaccine trial in UAE". The National. 13 August 2020. Retrieved 15 August 2020.
  11. "China's Sinopharm to test potential COVID-19 vaccine in Brazil". Reuters. 29 July 2020. Retrieved 15 August 2020.
  12. "China's Sinopharm starts Phase III trial of COVID-19 vaccine in Bahrain". Reuters. 10 August 2020. Retrieved 15 August 2020.
  13. "China to supply potential coronavirus vaccine to Pakistan: WSJ report". Dawn. 14 August 2020. Retrieved 15 August 2020.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.